Generic Drugs for Chronic Diseases: The Patent Cliff Playbook Every Pharma Strategist Needs
Chronic diseases kill 74% of all humans who die each year. That is not a warm-up statistic—it is the entire […]
Generic Drug Development Pitfalls: The ANDA, IP, and cGMP Playbook Analysts Actually Use
Generic medicines fill 89% of all U.S. prescriptions yet account for only 26% of total drug spend. That ratio defines
Generic Drug Development Pitfalls: The ANDA, IP, and cGMP Playbook Analysts Actually Use Read Post »
Drug Patent Expiration: The Complete Strategic Guide to Loss of Exclusivity, Lifecycle Management, and the $400 Billion Cliff
The $400 Billion Ticking Clock: Quantifying the Patent Cliff Between 2025 and 2030, the global pharmaceutical industry faces a Loss
The Russian Pharmaceutical Industry: A Definitive Guide to Strategic Evolution, Geopolitical Realities, and Market Sovereignty
Executive Market Assessment: The Sovereign Paradox The Russian pharmaceutical sector currently operates within a paradigm of aggressive state-managed isolationism, creating
505(b)(2) Strategy: The Complete Playbook for Portfolio Management, IP Defense, and Generic Launch
For pharma IP teams, portfolio managers, R&D leads, and institutional investors navigating the $300 billion patent cliff 1. The Strategic
Pharma Licensing Deals: The Complete IP, Valuation, and Deal Structure Playbook
The global pharmaceutical industry is running out of time. Between 2024 and 2030, roughly $200 billion in branded drug revenue
Pharma Licensing Deals: The Complete IP, Valuation, and Deal Structure Playbook Read Post »
Pharmaceutical Patent Use Codes: The Definitive Technical and Strategic Guide to Orange Book Method-of-Use Patents, Skinny Labeling, and Induced Infringement Risk
1. What Patent Use Codes Are and Why They Cost the Healthcare System $3.5 Billion per Year A patent use
Drug Patent Data: The Investor’s Edge in Pharma Stock Picking
Why Patent Data Outperforms Every Other Pharma Signal A company’s balance sheet is a photograph of last quarter. Its clinical
Drug Patent Data: The Investor’s Edge in Pharma Stock Picking Read Post »
Biosimilar Reimbursement Models: The Definitive Analyst’s Guide to Buy-and-Bill, PBM Dynamics, ASP Mechanics, and the Structural Forces Shaping Biologic Market Access
1. The Market Imperative: Biologics Cost 46% of U.S. Drug Spend at Less Than 2% of Volume Biologic drugs generated
